Enalapril therapy and thrombotic and inflammatory abnormalities in essential arterial hypertension

Aim. During enalapril therapy in essential arterial hypertension (EAH) patients, to assess correction of the factors determining arterial thrombosis and inflammatory changes in arterial wall. Material and methods. The study included 21 males with Stage II EAH. The authors analyzed cardiac ultrasound...

Full description

Saved in:
Bibliographic Details
Main Authors: O. M. Moiseeva, O. A. Berkovich, S. V. Villevalde, I. V. Emelyanov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2005-12-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1037
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. During enalapril therapy in essential arterial hypertension (EAH) patients, to assess correction of the factors determining arterial thrombosis and inflammatory changes in arterial wall. Material and methods. The study included 21 males with Stage II EAH. The authors analyzed cardiac ultrasound data, blood rheology, white blood cell (WBC) functional activity, plasma levels of von Willebrand factor (vWF) and intercellular adhesion molecules (ICAM). The second examination was performed after 24-week enalapril therapy (10-40 mg/d). Results. Enalapril therapy was associated with blood rheology improvement, WBC functional activity decrease, decline in vWF and ICAM plasma levels. Enalapril antihypertensive effect was combined with left ventricular hypertrophy (LVH) regression. Conclusion. In EAH patients, long-term enalapril therapy was associated with LVH regression, thrombo- and atherogenesis suppression.
ISSN:1728-8800
2619-0125